Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Multiple SC Doses of BI 655064 in Healthy Chinese Male Volunteers
NCT02331277Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2015
- Primary completion
- May 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in lupus nephritis (LN), systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) comparing BI 655064 with Placebo (2 arms). Primary endpoint: Percentage of Subjects With Drug-related Adverse Events up to 148 days. Started Sep 2015; status: completed.
02
Drugs
BI 655064
03
Conditions
lupus nephritis (LN)systemic lupus erythematosus (SLE)rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02331277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02331277.